Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer.

Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH.

Invest New Drugs. 2012 Dec;30(6):2371-6.

PMID:
22302349
[PubMed - indexed for MEDLINE]
2.

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF.

Cancer. 2001 Aug 1;92(3):569-77.

PMID:
11505401
[PubMed - indexed for MEDLINE]
3.

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, Stella PJ, Tenglin RC, Schaefer PL, Moore DF Jr, Alberts SR.

J Clin Oncol. 2007 Jun 20;25(18):2567-72.

PMID:
17577035
[PubMed - indexed for MEDLINE]
Free Article
4.

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

J Clin Oncol. 2010 Apr 1;28(10):1645-51. doi: 10.1200/JCO.2009.25.4433. Epub 2010 Mar 1.

PMID:
20194854
[PubMed - indexed for MEDLINE]
Free Article
5.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
[PubMed - indexed for MEDLINE]
Free Article
6.

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M.

Cancer. 2002 Feb 15;94(4):902-10.

PMID:
11920457
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.

Feliu J, Borrega P, León A, López-Gómez L, López M, Castro J, Belda-Iniesta C, Barriuso J, Martínez V, González-Barón M.

Cancer Chemother Pharmacol. 2011 Jan;67(1):215-21. doi: 10.1007/s00280-010-1472-0. Epub 2010 Oct 7.

PMID:
20927525
[PubMed - indexed for MEDLINE]
8.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

PMID:
11743211
[PubMed - indexed for MEDLINE]
Free Article
9.

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.

Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A; Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Lancet Oncol. 2008 Jan;9(1):39-44.

PMID:
18077217
[PubMed - indexed for MEDLINE]
10.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
[PubMed - indexed for MEDLINE]
11.

Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.

Ueno H, Okusaka T, Ikeda M, Morizane C, Ogura T, Hagihara A, Tanaka T.

Jpn J Clin Oncol. 2007 Jul;37(7):515-20. Epub 2007 Aug 2.

PMID:
17675286
[PubMed - indexed for MEDLINE]
Free Article
12.

Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.

Ardavanis A, Kountourakis P, Karagiannis A, Doufexis D, Tzovaras AA, Rigatos G.

Anticancer Res. 2009 Dec;29(12):5211-7.

PMID:
20044638
[PubMed - indexed for MEDLINE]
Free Article
13.

Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.

El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA.

J Clin Oncol. 2003 Aug 1;21(15):2920-5.

PMID:
12885810
[PubMed - indexed for MEDLINE]
Free Article
14.

Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.

Feliu J, Sáenz JG, Jaráiz AR, Castañón C, Cruz M, Fonseca E, Lomas M, Castro J, Jara C, Casado E, León A, Barón MG.

Cancer Chemother Pharmacol. 2006 Oct;58(4):419-26. Epub 2006 Jan 11.

PMID:
16404636
[PubMed - indexed for MEDLINE]
15.

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.

El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL.

Invest New Drugs. 2011 Aug;29(4):694-9. doi: 10.1007/s10637-010-9386-6. Epub 2010 Jan 27.

PMID:
20107864
[PubMed - indexed for MEDLINE]
16.

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.

J Clin Oncol. 2006 Jan 20;24(3):379-85. Epub 2005 Dec 12.

PMID:
16344320
[PubMed - indexed for MEDLINE]
Free Article
17.

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O'Reilly EM.

Ann Oncol. 2008 Jan;19(1):86-91. Epub 2007 Sep 17.

PMID:
17878176
[PubMed - indexed for MEDLINE]
Free Article
18.

A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing?

Clayton AJ, Mansoor AW, Jones ET, Hawkins RE, Saunders MP, Swindell R, Valle JW.

Pancreas. 2006 Jan;32(1):51-7.

PMID:
16340744
[PubMed - indexed for MEDLINE]
19.

Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma.

Bang S, Jeon TJ, Kim MH, Park JY, Park SW, Chung JB, Song SY.

Pancreatology. 2006;6(6):635-41. Epub 2006 Dec 6.

PMID:
17159377
[PubMed - indexed for MEDLINE]
20.

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K.

Cancer. 2006 Mar 15;106(6):1339-46.

PMID:
16475213
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk